OT mobile menu

Search form



Combination Therapy Active in Children, AYAs With Hodgkin Lymphoma

Brentuximab vedotin combined with gemcitabine may be a new treatment option for children and AYA patients with Hodgkin lymphoma.

Image © tomorn pukesorn/Shutterstock.com

Recent Content

The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.

Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.

Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies.

In a recent sub-analysis, lenvatinib was shown to improve both progression-free and overall survival in older patients with radioiodine-refractory thyroid cancer.

In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.

In this video, Dr. Edward Kim provides details on the TAPUR trial, which uses broad genomic test results to aid in precision medicine for cancer patients.

In this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.